{"id":181270,"date":"2017-03-04T01:23:37","date_gmt":"2017-03-04T06:23:37","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/stryker-nysesyk-target-price-raised-to-135-00-reported-today-breaking-finance-news\/"},"modified":"2017-03-04T01:23:37","modified_gmt":"2017-03-04T06:23:37","slug":"stryker-nysesyk-target-price-raised-to-135-00-reported-today-breaking-finance-news","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/stryker-nysesyk-target-price-raised-to-135-00-reported-today-breaking-finance-news\/","title":{"rendered":"Stryker (NYSE:SYK) target price raised to $135.00, reported today &#8230; &#8211; Breaking Finance News"},"content":{"rendered":"<p><p>      Yesterday Stryker (NYSE:SYK) traded -0.20% lower at $130.79.      The companys 50-day moving average is $124.46 and its      200-day moving average is $117.54. The last stock close price      is up 11.27% from the 200-day moving average, compared to the      S&P 500 which has increased 0.05% over the same time.      940,446 shares of the stock were exchanged, down from an      average trading volume of 1,320,280    <\/p>\n<p>      Stryker (NYSE:SYK) had its target price raised to $135.00 by      RBC Capital in a report released 3\/3\/2017. The new target      price indicates a possible upside of 0.03% based on the      company's last stock close price.    <\/p>\n<p>      Previously on Wednesday January 25, 2017, Canaccord reported      about Stryker (NYSE:SYK) raised the target price from $127.00      to $137.00. At the time, this indicated a possible upside of      0.13%.    <\/p>\n<\/p>\n<p>      Stryker has a price-earnings ratio of 30.07 with a one year      low of $98.00 and a one year high of $131.36 The companys      market cap is currently $0.    <\/p>\n<p>      In addition to RBC Capital reporting its stock price target,      a total of 24 analysts have released a research note on SYK.      The one year target is $116.50 with nine analysts rating the      company a strong buy, eight equity analysts rating the      company a buy, nine equity analysts rating the company a      hold, 2 brokers rating the stock a underperform, and finally      1 broker rating the stock a sell.    <\/p>\n<p>      Stryker Corporation is a medical technology company. The      Company offers a range of medical technologies, including      orthopedic, medical and surgical, and neurotechnology and      spine products. The Company's segments include Orthopaedics;      MedSurg; Neurotechnology and Spine, and Corporate and Other.      The Orthopaedics segment includes reconstructive (hip and      knee) and trauma implant systems and other related products.      The MedSurg segment includes surgical equipment and surgical      navigation systems; endoscopic and communications systems;      patient handling, emergency medical equipment, intensive care      disposable products; reprocessed and remanufactured medical      devices, and other related products. The Neurotechnology and      Spine segment includes neurovascular products, spinal implant      systems and other related products. The Company's products      include implants, which are used in joint replacement and      trauma surgeries, and other products that are used in a range      of medical specialties.    <\/p>\n<p>      Receive News & Ratings Via Email - Enter      your email address below to receive a concise daily summary      of the latest news and analysts' ratings with       MarketBeat.com's FREE daily email newsletter.    <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Go here to see the original: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/breakingfinancenews.com\/investing\/stryker-nysesyk-target-price-raised-to-135-00-reported-today-by-rbc-capital\/193504\/\" title=\"Stryker (NYSE:SYK) target price raised to $135.00, reported today ... - Breaking Finance News\">Stryker (NYSE:SYK) target price raised to $135.00, reported today ... - Breaking Finance News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Yesterday Stryker (NYSE:SYK) traded -0.20% lower at $130.79.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/stryker-nysesyk-target-price-raised-to-135-00-reported-today-breaking-finance-news\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-181270","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/181270"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=181270"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/181270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=181270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=181270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=181270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}